Company profilePharmaceutical#477 of 1,318 in Pakistan3 DRAP alerts

Platinum Pharmaceautical

Pharmaceutical company · 30 brands · 52 molecules

Ranked #8 of 74 companies in Pain Management

30 registered products 19 pharmaceutical brands 52 distinct molecules 3 DRAP alerts

Company overview

registered products

pharmaceutical brands

distinct molecules

therapeutic classes

DRAP alerts

Platinum Pharmaceautical is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 30 product registrations across 52 distinct molecules. Its portfolio is concentrated in Pain Management and Antiinflammatory And Antirheumatic Products. DRAP has issued 3 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Platinum

3 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Neuro 2

Cereginsoln15mlRs 76.35 Teloxoral120mlRs 333

Respiratory Care 1

Pulmitacsoln60mlRs 117

Top molecules by brand count

Naproxen4 brands

Losartan2 brands

Co-Dergocrine2 brands

Carbocisteine2 brands

Oxcarbazepine2 brands

Doxycycline1 brand

Cefadroxil1 brand

Hydrochlorothiazide1 brand

Losartan Potassium1 brand

Losartan Potassium ...... 50 Mg1 brand

Therapeutic classes

Conditions treated

Price band (DRAP official ceilings)

Registered products priced by source

DRAP-official18 products · Rs 194.59 – Rs 5,557.06

DVAGO43 products · Rs 100.33 – Rs 936

Servaid43 products · Rs 76.35 – Rs 2,585

Median across source: Rs 266

Regulatory record

3 alerts in the DRAP feed we track.

Advisory to Therapeutic Goods Manufacturers: Measures to Prevent DEG/EG Contamination in O

2025-10-16

ADVISORY TO THERAPEUTIC GOODS MANUFACTURERS: MEASURES TO PREVENT DEG/EG CONTAMINATION IN O

2025-04-21

Safety Alert of Falsified Medical Products, including In Vitro Diagnostics, that claim to

2020-04-14

Competitive set

Companies whose registered portfolio overlaps most with this one.

Hiranis Pharmaceuticals (Pvt) Limited19 shared molecules

KAIZEN PHARMACEUTICALS PVT LTD.18 shared molecules

BIO LABS (PVT) LTD.18 shared molecules

Novartis Pharmaceuticals (Pvt) Ltd.16 shared molecules

MEDIATE PHARMACEUTICALS (PVT) LTD16 shared molecules

PLATINUM PHARMACEUTICALS (PVT.) LTD.15 shared molecules

Horizon Pharmaceuticals (Pvt) Limited14 shared molecules

NEUTRO PHARMA (PVT) LTD.14 shared molecules

NABIQASIM INDUSTRIES (PVT) LTD.13 shared molecules

VALOR PHARMACEUTICALS13 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Hiranis Pharmaceuticals (Pvt) Limited holds 98 molecules not in this portfolio

KAIZEN PHARMACEUTICALS PVT LTD. holds 34 molecules not in this portfolio

BIO LABS (PVT) LTD. holds 139 molecules not in this portfolio

Get the full profile for Platinum

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included